Amarin Corp Plc (AMRN)

[drrc1949]

The majority of docs whom I've heard from recognize that this is not a study of CVD or T2D markers, it is an outcomes study. Those who understand this seem to have little concern about the placebo since the data show consistent outcomes regardless of cholesterol or triglyceride levels.

Personally I think the FDA will be convinced based on these same data. If it isn't, then I think the outcry from patients and physicians may help them to fulfill their useful function of drug approval. (I don't mind if they ask for more data...as long as they don't hold up the approval.)